Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) – Research analysts at FBR & Co upped their FY2019 earnings per share estimates for shares of Keryx Biopharmaceuticals in a research note issued to investors on Monday. FBR & Co analyst C. James now forecasts that the brokerage will post earnings of $0.97 per share for the year, up from their prior estimate of $0.77. FBR & Co currently has a “Market Perform” rating and a $7.00 target price on the stock. FBR & Co also issued estimates for Keryx Biopharmaceuticals’ FY2020 earnings at $1.19 EPS.
Several other research firms have also recently issued reports on KERX. Maxim Group cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a report on Wednesday, July 13th. Vetr cut shares of Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $5.93 price target on the stock. in a report on Monday, October 3rd. Brean Capital cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. Finally, Ladenburg Thalmann upped their price target on shares of Keryx Biopharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. One analyst has rated the stock with a sell rating, eight have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $8.44.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 2.44% during mid-day trading on Wednesday, hitting $4.40. 1,335,625 shares of the stock traded hands. The stock’s market cap is $465.94 million. The firm’s 50 day moving average price is $4.87 and its 200-day moving average price is $5.47. Keryx Biopharmaceuticals has a 12-month low of $2.80 and a 12-month high of $7.80.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.14. The firm earned $9.30 million during the quarter, compared to analysts’ expectations of $8.60 million. Keryx Biopharmaceuticals had a negative net margin of 590.50% and a negative return on equity of 172.04%. The firm’s revenue was up 272.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.26) EPS.
A number of institutional investors have recently made changes to their positions in KERX. Creative Planning raised its position in shares of Keryx Biopharmaceuticals by 19.5% in the third quarter. Creative Planning now owns 36,789 shares of the biopharmaceutical company’s stock worth $195,000 after buying an additional 6,000 shares in the last quarter. Stifel Financial Corp bought a new position in shares of Keryx Biopharmaceuticals during the second quarter worth about $170,000. Paloma Partners Management Co bought a new position in shares of Keryx Biopharmaceuticals during the second quarter worth about $536,000. A.R.T. Advisors LLC bought a new position in shares of Keryx Biopharmaceuticals during the second quarter worth about $471,000. Finally, Parametric Portfolio Associates LLC raised its position in shares of Keryx Biopharmaceuticals by 5.4% in the second quarter. Parametric Portfolio Associates LLC now owns 25,951 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 1,328 shares in the last quarter. Hedge funds and other institutional investors own 61.15% of the company’s stock.
In related news, CFO Scott A. Holmes sold 4,935 shares of the stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $7.36, for a total value of $36,321.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.08% of the stock is currently owned by corporate insiders.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.